Iovance Bio Taps Roche’s Graf Finckenstein for Chief Medical Officer

Iovance Biotherapeutics (NASDAQ: [[ticker:IOVA]]) has appointed Graf Finckenstein to serve as its chief medical officer. Finckenstein comes to the San Carlos, CA, cancer drug developer from Roche, where he was global head of oncology translational medicine. His experience also includes positions at Bristol-Myers Squibb (NYSE: [[ticker:BMY]]). Iovance, which is developing a type of cancer treatment called a tumor-infiltrating lymphocyte, has four experimental therapies in mid-stage clinical trials.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan